In-vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents

Journal of Medical Microbiology

Volumn 44, Issue 4, 1996, Pages 311-316

  Wu, T ^a   Samaranayake, L P ^a   Cao, B Y ^b   Wang, J ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; MICONAZOLE; NYSTATIN; PROTEINASE;

ARTICLE; ATTENUATION; BACTERIAL COLONIZATION; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; ENZYME SYNTHESIS; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOUTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0029943720     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-44-4-311     Document Type: Article

References (29)

1. Macdonald F, Odds FC. Virulence for mice of a proteinase-secreting strain of Candida albicans and a proteinase-deficient mutant. J Gen Microbiol 1983; 29: 431-438.
2. Rüchel R. Properties of a purified proteinase from the yeast Candida albicans. Biochem Biophys Acta 1981; 659: 99-113.
3. Kwong-Chung KJ, Lehman D, Good C, Magee PT. Genetic evidence for role of extracellular proteinase in virulence of Candida albicans. Infect Immun 1985; 49: 571-575.
4. Rüchel R, Tegeler R, Trost M. A comparison of secretory proteinases from different strains of Candida albicans. Sabouraudia 1982; 20: 233-244.
5. Kaminishi H, Miyaguchi H, Tamaki T et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995; 63: 984-988.
6. Negi M, Tsuboi R, Matsui T, Ogawa H. Isolation and characterization of proteinase from Candida albicans: substrate specificity. J Invest Dermatol 1984; 83: 32-36.
7. Hattori M, Yoshiura K, Negi M, Ogawa H. Keratinolytic proteinase produced by Candida albicans. Sabouraudia 1984; 22: 175-183.
8. Macdonald F, Odds FC. Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. J Med Microbiol 1980; 13: 423-435.
9. Rüchel R. A variety of Candida proteinases and their possible targets of proteolytic attack in the host. Zentralbl Backteriol Mikrobiol Hyg [A] 1984; 257: 266-274.
10. Datta A, Ganesan K, Natarajan K. Current trends in Candida albicans research. Adv Microbiol Physiol 1989; 30: 53-88.
11. Staib F. Serum-proteins as nitrogen source for yeastlike fungi. Sabouraudia 1965; 4: 187-193.
12. Rüchel R. Virulence factors of Candida species. In: Samaranayake LP, MacFarlane TW (eds) Oral candidosis. London, Wright-Butterworth. 1990: 47-65.
13. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992; 73: 171-180.
14. Holmstrup P, Samaranayake LR Acute and AIDS-related oral candidoses. In: Samaranayake LP, MacFarlane TW (eds) Oral candidosis. London, Wright-Butterworth. 1990: 133-155.
15. De Bernardis F, Boccanera M, Rainaldi L, Guerra CE, Quinti L, Cassone A. The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur J Epidemiol 1992; 8: 362-367.
16. McCullough M, Ross B, Reade PC. Oral Candida albicans from patients infected with the human immunodeficiency virus and characterization of a genetically distinct subgroup of Candida albicans. Austr Dent J 1995; 40: 91-97.
17. Angiolella L, De Bernardis F, Bromuro C, Modello F, Ceddia T, Cassone A. The effect of antimycotics on secretory acid proteinase of Candida albicans. J Chemother 1990; 2: 55-61.
18. McGinnis MG, Rinaldi MG. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In: Lorian V (ed) Antibiotics in laboratory medicine, 3rd edn. Baltimore, Williams and Wilkins. 1991: 198-278.
19. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol 1994; 78: 202-210.
20. Germaine GR, Tellefson LM, Johnson GL. Proteolytic activity of Candida albicans: action on human salivary proteins. Infect Immun 1978; 22: 861-866.
21. Samaranayake LP, Hughes A, MacFarlane TW. The proteolytic potential of Candida albicans in human saliva supplemented with glucose. J Med Microbiol 1984; 17: 13-22.
22. Samaranayake YH, MacFarlane TW, Samaranayake LP, Aitchison T. The in vitro proteolytic and saccharolytic activity of Candida species in human saliva. Oral Microbiol Immunol 1994; 9: 229-235.
23. Mason DK, Chisholm DM. Salivary glands in health and disease. London: W B Saunders. 1975: 410.
24. Atkinson JC, Yeh CK, Bermudez D, Fox PC, Baum BJ. Longitudinal evaluation of major salivary gland function in HIV-1 infected patients. J Oral Pathol Med 1989; 18: 469-470.
25. Atkinson JC, Yeh CK, Oppenheim FG, Bermudez D, Baum BJ, Fox PC. Evaluation of salivary antimicrobial proteins following HIV-1 infection. Acquir Immune Defic Syndr 1990; 3: 41-48.
26. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 1992; 21: 209-213.
27. Marder MZ, Barr CE, Mandel ID. Cytomegalovirus presence and salivary composition in acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol 1985; 60: 372-376.
28. Ogrydziak DM. Yeast extracellular proteases. Crit Revi Biotechnol 1993; 13: 1-55.
29. Samaranayake LP. Superficial fungal infections. In: Scully C (ed) Current opinions in Dentistry. Philadelphia, Current Science. 1991: 415-422.